Labiotech expects approved CRISPR treatments for sickle cell anemia to bring clinical gene editing firmly into the mainstream in 2024.
When it comes to recent biotechnology breakthroughs in the healthcare world, industry news sources from Labiotech to Select Science place advancements in gene editing using CRISPR technology at the very top of the list. Labiotech expects approved CRISPR treatments for sickle cell anemia to bring clinical gene editing firmly into the mainstream in 2024. Select Science praises CRISPR technologies from Thermo Fisher Scientific and Merck KGaA/MilliporeSigma for breaking new ground in terms of enhancing gene editing workflow and developing novel therapeutic approaches.